Torrent Pharmaceuticals

Torrent Pharmaceuticals on Tuesday said it has forayed into the over-the-counter segment in the country with Shelcal 500, a calcium supplement brand. With its composition of 500mg Calcium and 250 IU of Vitamin D3, Shelcal 500 helps optimise calcium absorption, increases bone density, improves muscle strength and helps boost immunity. The calcium is sourced from natural ingredients like oyster shell, having good absorption/bioavailability in the body. "With Shelcal's entry into OTC, the brand is poised to become the largest calcium supplement brand in India," Torrent Pharmaceuticals Director Aman Mehta said in a statement. According to studies, 40.6 per cent of Indians are calcium-deficient, while 79 per cent are Vitamin D-deficient.

Torrent Pharma's revenues came in at Rs 2,491 crore for the quarter under review. The Ebitda margins were at 29.1 per cent while gross margins were 71 per cent during Q3FY23

Torrent Pharma on Wednesday said its consolidated net profit increased by 14 per cent to Rs 283 crore in the third quarter ended December 31, 2022. The drug firm had reported a net profit of Rs 249 crore in the October-December period of previous fiscal. Net sales increased to Rs 2,459 crore in the quarter under review as against Rs 2,092 crore in the year-ago period, the company said in a regulatory filing. The company's board, which met on Wednesday, declared an interim dividend of Rs 14 (280 per cent) per share of Rs 5 each. On Wednesday, shares of the company ended 1.86 per cent down at Rs 1,557.50 apiece on the BSE.

Business Standard brings you the top headlines at this hour

After the anti-diabetic market, India's cardiac market in for a shake-up

Share of India revenue in home-grown firms' consolidated turnover rising over the years

According to GT Bharat's monthly Dealtracker, the biggest deal in October was Torrent Pharma's $250 million acquisition of Curatio Healthcare

The Pharma benchmark has outperformed the overall market in recent trading sessions; sustenance above 200-DMA is likely to trigger further gains for it

CLOSING BELL: ITC, Dr Reddy's Labs, Tata Steel, Sun Pharma, M&M, NTPC, and Nestle India were the top large-cap winners, while Asian Paints, Tech M, Wipro, TCS, Titan, Kotak Bank sank

Sun Pharmaceutical seems set to register a new 52-week high; while Tata Motors and Torrent Pharmaceuticals are yet to take-off their respective obstacles, charts show.

Sales trajectory in domestic formulations and resolution of regulatory issues are other triggers

Stocks to Watch: Dr Reddy's has received US FDA nod for marketing Timolol Maleate, which is used to treat Glaucoma

First major acquisition by Aman Mehta after taking charge at Torrent Pharma in August

Torrent Pharmaceuticals on Tuesday said it will acquire Curatio Healthcare for Rs 2,000 crore to strengthen its presence in the dermatology segment. The company has entered into definitive agreements to acquire 100 per cent of Curatio Healthcare for Rs 2,000 crore, Torrent Pharmaceuticals said in a regulatory filing. "The consideration includes Rs 115 crore (on the date of signing) of cash and cash equivalents in the acquired business indicating an enterprise value of Rs 1,885 crore," it added. The acquisition offers Torrent the opportunity to enhance its presence in dermatology with a differentiated portfolio and is a strong strategic fit, Torrent Pharmaceuticals Director Aman Mehta said. "Curatio has built a commendable set of high market share brands in cosmetic and pediatric dermatology that we look forward to adding to our product offerings," he added. Chennai-headquartered Curatio has a portfolio of over 50 brands, including Tedibar, Atogla, Spoo, B4 Nappi and Permite, in th

Reliance Capital is undergoing a bankruptcy process and the administrator had sought offers for the entire company and for its various business clusters

According to reports, Torrent Pharmaceuticals is set to sign a deal to acquire Curatio Healthcare, a maker of skincare products, for Rs 2100 crore.

A company called Torrent Diagnostics Private Ltd was incorporated in February this year and has a Torrent Pharmaceuticals executive director as one of its directors

Cost savings could drive Torrent Pharma's margins higher in the near term

Styptovit-E, a gynaecology product, has an estimated market size of roughly Rs 500 crore, according to data from AIOCD, a pharmaceutical market research company

In Q4, the company posted net loss of Rs 118 crore against profit of Rs 324 crore in the year ago quarter